Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H12FN5O4 |
| Molecular Weight | 284.2343 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC2=C(N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3[18F])C(=O)N1
InChI
InChIKey=UXUZARPLRQRNNX-YXAALHNKSA-N
InChI=1S/C10H12FN5O4/c11-4-6(18)3(1-17)20-9(4)16-2-13-5-7(16)14-10(12)15-8(5)19/h2-4,6,9,17-18H,1H2,(H3,12,14,15,19)/t3-,4+,6-,9-/m1/s1/i11-1
| Molecular Formula | C10H12FN5O4 |
| Molecular Weight | 284.2343 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:36:37 UTC 2023
by
admin
on
Sat Dec 16 11:36:37 UTC 2023
|
| Record UNII |
X96PT3B08G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C120100
Created by
admin on Sat Dec 16 11:36:37 UTC 2023 , Edited by admin on Sat Dec 16 11:36:37 UTC 2023
|
PRIMARY | |||
|
1268848-88-9
Created by
admin on Sat Dec 16 11:36:37 UTC 2023 , Edited by admin on Sat Dec 16 11:36:37 UTC 2023
|
PRIMARY | |||
|
135564639
Created by
admin on Sat Dec 16 11:36:37 UTC 2023 , Edited by admin on Sat Dec 16 11:36:37 UTC 2023
|
PRIMARY | |||
|
X96PT3B08G
Created by
admin on Sat Dec 16 11:36:37 UTC 2023 , Edited by admin on Sat Dec 16 11:36:37 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> SUBSTRATE |
Marker for activated T-cells.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Stanford University; Developer: CellSight Technologies; Class: Imaging agent, Radiopharmaceutical diagnostics, Radiopharmaceutical; Mechanism of Action: Ionising radiation emitter, Positron-emission tomography enhancer; Available For Licensing: Yes; Highest Development Phase: Preclinical for Cancer; Most Recent Events: 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA (IV, Injection), 06 Jan 2015 18(F)F AraG is available for licensing as of 06 Jan 2015. http://www.cellsighttech.com/services-products/products.html, 06 Jan 2015 CellSight Technologies plans a phase I trial for Cancer (Diagnosis) in USA (NCT02323893)
|
